Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1626 1627
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18548580 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | Non-Final OA | THE BROAD INSTITUTE, INC. |
| 18014163 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VI | Non-Final OA | BASF SE |
| 17693901 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 17905487 | FUNGICIDAL COMPOSITIONS | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 17911346 | TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS AND COMPOUNDS FOR SAME | Non-Final OA | Board of Regents, The University of Texas System |
| 17736496 | COMPOSITIONS AND METHODS USING AT LEAST ONE OF OLEUROPEIN OR A METABOLITE THEREOF TO TREAT OR PREVENT MUSCLE FATIGUE FROM EXERCISE AND/OR FOR RESISTANCE TO MUSCLE FATIGUE FROM EXERCISE | Non-Final OA | SOCIÉTÉ DES PRODUITS NESTLÉ S.A. |
| 18038309 | Combined Therapy Against Cancer | Non-Final OA | UNIVERSITAT POLITÈCNICA DE CATALUNYA |
| 18258013 | USE OF DHODH INHIBITOR FOR CONTROLLING RESISTANT PHYTOPATHOGENIC FUNGI IN CROPS | Non-Final OA | BAYER AKTIENGESELLSCHAFT |
| 17909271 | USE OF QX314 TO PREVENT SYMPATHOEXCITATION ASSOCIATED WITH ADMINISTRATION OF TRPV1 MODULATORS | Final Rejection | NEUCURES, INC. |
| 17922624 | SUBSTITUTED TOLYL FUNGICIDES AND THEIR MIXTURES | Non-Final OA | FMC Corporation |
| 17419904 | THERAPEUTIC COMBINATIONS AS ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE | Final Rejection | The Scripps Research Institute |
| 17484628 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Final Rejection | Arvinas Operations, Inc. |
| 17577824 | PHARMACEUTICAL COMPOSITION COMPRISING AN INDACATEROL COMPOUND, A PHARMACEUTICALLY ACCEPTABLE SALT OF GLYCOPYRROLATE AND 1,1-DIFLUOROETHANE | Non-Final OA | MEXICHEM FLUOR S.A. DE C.V. |
| 18005851 | CANNABIDIOL FOR USE IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | Non-Final OA | GW Research Limited |
| 17845399 | Pharmaceutical Composition for Treatment or Prevention of Multiple Inflammatory disorders | Non-Final OA | AARDVARK THERAPEUTICS, INC. |
| 17336546 | Methods For Reducing Binge Or Compulsive Eating | Final Rejection | Nalpropion Pharmaceuticals LLC |
| 18041221 | No Rinse Disinfectant with Virucidal Properties Against Non-Enveloped Viruses | Non-Final OA | LONZA, LLC |
| 18002036 | THYROMIMETICS | Non-Final OA | Autobahn Therapeutics, Inc. |
| 17923105 | VITAMIN A FOR USE IN THE TREATMENT OF TRAUMATIC BRAIN INJURY | Non-Final OA | REGENALL LIMITED |
| 17492169 | TISSUE REPAIR | Final Rejection | Regenall Limited |
| 17943646 | COMPOSITIONS AND METHODS PROVIDING NUTRITIONAL AND OTHER BENEFITS HAVING ANTIVIRAL PROPERTIES | Non-Final OA | Furst-McNess Company |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy